# TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT

> **NCT07139405** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Myopharm Limited** · enrollment: 90 (estimated)

## Conditions studied

- Type 2 Diabetes (T2DM)

## Interventions

- **DRUG:** Metformin XR 1000mg
- **DRUG:** Valsartan 80mg Tablet
- **DRUG:** Valsartan 160mg tablet
- **DRUG:** Celecoxib (Celebrex®) 100mg
- **DRUG:** Celecoxib (Celebrex®) 200mg
- **DRUG:** Metformin XR 500 mg

## Key facts

- **NCT ID:** NCT07139405
- **Lead sponsor:** Myopharm Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07139405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07139405, "TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07139405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*